All Photos(1)

Documents

C4042

Captopril

Name: Captopril
Brand: SIGMA

≥98% (HPLC), powder, angiotensin converting enzyme inhibitor

Synonym(s):

N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₉H₁₅NO₃S

CAS Number:

62571-86-2

Molecular Weight:

217.29

Beilstein:

477887

EC Number:

263-607-1

MDL number:

MFCD00168073

UNSPSC Code:

12352200

PubChem Substance ID:

57654003

NACRES:

NA.77

product name

Captopril, ≥98% (HPLC), powder

biological source

synthetic

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to off-white

mp

104-108 °C (lit.)

solubility

water: 100 mg/mL, clear to very slightly hazy, colorless to faintly yellow

originator

Bristol-Myers Squibb

storage temp.

room temp

SMILES string

C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O

InChI

1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1

InChI key

FAKRSMQSSFJEIM-RQJHMYQMSA-N

Gene Information

human ... ACE(1636) , AGTR1(185) , AGTR2(186) , ECE1(1889)
rat ... Ace(24310)

Looking for similar products? Visit Product Comparison Guide

Application

Captopril has been used:

to examine the influence of timing of captopril treatment on efficacy in transverse aortic constriction (TAC) mice
as an angiotensin-converting enzyme inhibitor and orally administered to unrestrained Wistar Kyoto rats in an approach to study its effects of angiogenesis inhibition and interdependency with other drugs
used as a positive control in spectrophotometric assay to study the angiotensin-converting enzyme inhibitory activity

Biochem/physiol Actions

Captopril is known to decrease the cardiovascular complications arising due to myocardial infarction. It is an effective drug in treating diabetic nephropathy and renal disease. Captopril acts by reducing cardiac related inflammation, fibrosis and calcification.

Angiotensin converting enzyme inhibitor. Inhibits the formation of angiotensin II, a bioactive peptide that stimulates angiogenesis and increases microvessel density.

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound is featured on the Neuropeptidases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

GHS08

Signal Word

Danger

Hazard Statements

H341,H360F

Precautionary Statements

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Muta. 2 - Repr. 1B

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

ACE Inhibitory Properties and Phenolics Profile of Fermented Flours and of Baked and Digested Biscuits from Buckwheat.

Henryk Zieliński et al.

Foods (Basel, Switzerland), 9(7) (2020-07-03)

The angiotensin converting enzyme (ACE) inhibitory activity and phenolics profile of fermented flours and of baked and digested buckwheat biscuits was studied. The fermentation of buckwheat flour by select lactic acid bacteria (LAB) caused a decrease in ACE inhibitory activity

Captopril prevents experimental autoimmune myocarditis

Godsel LM, et al.

Journal of Immunology, 171(1), 346-352 (2003)

Identification of antihypertensive peptides derived from low molecular weight casein hydrolysates generated during fermentation by Bifidobacterium longum KACC 91563

Ha GE, et al.

Korean journal for food science of animal resources, 35(6), 738-738 (2015)

The primary benefits of angiotensin-converting enzyme inhibition on cardiac remodeling occur during sleep time in murine pressure overload hypertrophy.

Tami A Martino et al.

Journal of the American College of Cardiology, 57(20), 2020-2028 (2011-05-14)

Our objective was to test the hypothesis that there is a significant diurnal variation for the therapeutic benefit of angiotensin-converting enzyme (ACE) inhibitors on pressure-overload cardiovascular hypertrophy. Physiological and molecular processes exhibit diurnal rhythms that may affect efficacy of disease

The primary benefits of angiotensin-converting enzyme inhibition on cardiac remodeling occur during sleep time in murine pressure overload hypertrophy

Martino TA, et al.

Journal of the American College of Cardiology, 57(20), 2020-2028 (2011)

View All Related Papers

Articles

Critical Inhibitor Characteristics to Consider

Discover critical characteristics to consider when working with enzyme inhibitors, such as cell permeability, the prozone effect, and Lipinski’s rule of 5.

Discover Bioactive Small Molecules for ADME/Tox

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service